Rationalisation of the purification process for a phage active pharmaceutical ingredient

被引:2
|
作者
Lapras, B. [1 ,2 ]
Marchand, C. [1 ,3 ]
Merienne, C. [1 ]
Medina, M. [3 ,4 ]
Kolenda, C. [3 ,4 ]
Laurent, F. [3 ]
Pirot, F. [1 ,2 ]
机构
[1] Hop Edouard Herriot, Hosp Civils Lyon, FRIPHARM, Pharm Dept, F-69437 Lyon, France
[2] Claude Bernard Lyon 1 Univ, CNRS, UMR 5305, Inst Biol & Chim Prot IBCP,French Natl Ctr Sci Res, F-69007 Lyon, France
[3] Croix Rousse Hosp, Hosp Civils Lyon, French Natl Reference Ctr Staphylococci, Bacteriol Dept, F-69317 Lyon, France
[4] Claude Bernard Lyon 1 Univ, CNRS, INSERM, UMR 5308,U1111,Ctr Int Rech Infectiol CIRI, F-69365 Lyon, France
关键词
Bacteriophages; Phage active pharmaceutical ingredient; Phage purification; Phage lysate impurities; Separation unit operations; Rationalisation of process development; AFFECTING ENDOTOXIN REMOVAL; VIRUS PURIFICATION; AQUEOUS-SOLUTIONS; BACTERIOPHAGE; THERAPY; RNA; ELECTROKINETICS; ULTRAFILTRATION; CHROMATOGRAPHY; AGGREGATION;
D O I
10.1016/j.ejpb.2024.114438
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The resurgence of phage therapy, once abandoned in the early 20th century in part due to issues related to the purification process and stability, is spurred by the global threat of antibiotic resistance. Engineering advances have enabled more precise separation unit operations, improving overall purification efficiency. The present review discusses the physicochemical properties of impurities commonly found in a phage lysate, e.g., contaminants, phage-related impurities, and propagation-related impurities. Differences in phages and bacterial impurities properties are leveraged to elaborate a four-step phage purification process: clarification, capture and concentration, subsequent purification and polishing. Ultimately, a framework for rationalising the development of a purification process is proposed, considering three operational characteristics, i.e., scalability, transferability to various phages and duration. This guide facilitates the preselection of a sequence of unit operations, which can then be confronted with the expected impurities to validate the theoretical capacity of the process to purify the phage lysate.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Crystallization of an active pharmaceutical ingredient that oils out
    Lu, Jie
    Li, Yi-Ping
    Wang, Jing
    Ren, Guo-Bin
    Rohani, Sohrab
    Ching, Chi-Bun
    SEPARATION AND PURIFICATION TECHNOLOGY, 2012, 96 : 1 - 6
  • [22] Process Design and Optimization for the Continuous Manufacturing of Nevirapine, an Active Pharmaceutical Ingredient for HIV Treatment
    Diab, Samir
    McQuade, D. Tyler
    Gupton, B. Frank
    Gerogiorgis, Dimitrios I.
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (03) : 320 - 333
  • [23] Structure of the active pharmaceutical ingredient bismuth subsalicylate
    Erik Svensson Grape
    Victoria Rooth
    Mathias Nero
    Tom Willhammar
    A. Ken Inge
    Nature Communications, 13
  • [24] Diosgenin: an important natural pharmaceutical active ingredient
    Huang, Nannan
    Yu, Dan
    Wu, Junkai
    Du, Xiaowei
    FOOD SCIENCE AND TECHNOLOGY, 2022, 42
  • [25] Structure of the active pharmaceutical ingredient bismuth subsalicylate
    Grape, Erik Svensson
    Rooth, Victoria
    Nero, Mathias
    Willhammar, Tom
    Inge, A. Ken
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [26] Integrated Purification and Formulation of an Active Pharmaceutical Ingredient via Agitated Bed Crystallization and Fluidized Bed Processing
    Stocker, Michael W.
    Harding, Matthew J.
    Todaro, Valerio
    Healy, Anne Marie
    Ferguson, Steven
    PHARMACEUTICS, 2022, 14 (05)
  • [27] Integration of Active Pharmaceutical Ingredient production into a pharmaceutical Lean Learning Factory
    Petrusch, Natalie
    Sieckmann, Felix
    Menn, Jan P.
    Kohl, Holger
    RESEARCH. EXPERIENCE. EDUCATION., 2019, 31 : 245 - 250
  • [28] Mathematical Modeling and Optimization to Inform Impurity Control in an Industrial Active Pharmaceutical Ingredient Manufacturing Process
    Diab, Samir
    Christodoulou, Charalampos
    Taylor, George
    Rushworth, Philip
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2022, 26 (10) : 2864 - 2881
  • [29] Process analytical technology (PAT): applications to flow processes for active pharmaceutical ingredient (API) development
    Talicska, Courtney N.
    O'Connell, Eamon C.
    Ward, Howard W.
    Diaz, Angel R.
    Hardink, Mark A.
    Foley, David A.
    Connolly, Douglas
    Girard, Kevin P.
    Ljubicic, Tomislav
    REACTION CHEMISTRY & ENGINEERING, 2022, 7 (06) : 1419 - 1428
  • [30] Effect of process scale-up on the dissolution of granules with a high content of active pharmaceutical ingredient
    Smrcka, David
    Dohnal, Jiri
    Stepanek, Frantisek
    POWDER TECHNOLOGY, 2015, 285 : 88 - 95